The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
<h4>Objectives</h4>To evaluate the prognostic effect of the Heterogeneous nuclear ribonucleoprotein type M (HNRPM) and Solute carrier 1A5 (SLC1A5) in FIGO-stages I-II epithelial ovarian cancer.<h4>Methods</h4>A retrospective cohort study was designed to investigate the progno...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0179363&type=printable |
| _version_ | 1826579440987013120 |
|---|---|
| author | Kathrine Bjersand Tomas Seidal Inger Sundström-Poromaa Helena Åkerud Ingiridur Skirnisdottir |
| author_facet | Kathrine Bjersand Tomas Seidal Inger Sundström-Poromaa Helena Åkerud Ingiridur Skirnisdottir |
| author_sort | Kathrine Bjersand |
| collection | DOAJ |
| description | <h4>Objectives</h4>To evaluate the prognostic effect of the Heterogeneous nuclear ribonucleoprotein type M (HNRPM) and Solute carrier 1A5 (SLC1A5) in FIGO-stages I-II epithelial ovarian cancer.<h4>Methods</h4>A retrospective cohort study was designed to investigate the prognostic effect of HNRPM and SLC1A5, and the association with clinical-pathologic characteristics in 131 patients with FIGO-stages I-II epithelial ovarian cancer. Tissue microarrays were constructed and protein levels were assessed by immunohistochemistry (IHC).<h4>Results</h4>Positive HRNPM status was associated with positive staining for PUMA (P = 0.04), concomitant PUMA and p21 staining (P = 0.005), and VEGF-R2 (P = 0.003). Positive SLC1A5 staining was associated with positive staining of p27 (P = 0.030), PUMA (P = 0.039), concomitant PUMA and p27 staining, and VEGF-R2 (P = 0.039). In non-serous tumors (n = 72), the SLC1A5 positivity was associated with recurrent disease (P = 0.01). In a multivariable logistic regression analysis FIGO-stage (OR = 12.4), tumor grade (OR = 5.1) and SLC1A5 positivity (OR = 0.1) were independent predictive factors for recurrent disease. Disease-free survival (DFS) in women with SLC1A5-positive non-serous tumors was 92% compared with of 66% in patients with SLC1A5-negative non-serous tumors (Log-rank = 15.343; P = 0.008). In Cox analysis with DFS as endpoint, FIGO-stage (HR = 4.5) and SLC1A5 status (HR = 0.3) were prognostic factors.<h4>Conclusions</h4>As the proteins HRNPM and SLC1A5 are associated with the cell cycle regulators p21 or p27, the apoptosis regulators PTEN and PUMA, and the VEGF-R2 it is concluded that both proteins have role in the pathogenesis of ovarian cancer. In patients with non-serous ovarian cancer SLC1A5 protects from recurrent disease, presumably by means of biological mechanisms that are unrelated to cytotoxic drug sensitivity. |
| first_indexed | 2024-12-14T10:57:04Z |
| format | Article |
| id | doaj.art-818ba5719ccc419e8e376d44675e3f65 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2025-03-14T14:18:19Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-818ba5719ccc419e8e376d44675e3f652025-02-27T05:32:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017936310.1371/journal.pone.0179363The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.Kathrine BjersandTomas SeidalInger Sundström-PoromaaHelena ÅkerudIngiridur Skirnisdottir<h4>Objectives</h4>To evaluate the prognostic effect of the Heterogeneous nuclear ribonucleoprotein type M (HNRPM) and Solute carrier 1A5 (SLC1A5) in FIGO-stages I-II epithelial ovarian cancer.<h4>Methods</h4>A retrospective cohort study was designed to investigate the prognostic effect of HNRPM and SLC1A5, and the association with clinical-pathologic characteristics in 131 patients with FIGO-stages I-II epithelial ovarian cancer. Tissue microarrays were constructed and protein levels were assessed by immunohistochemistry (IHC).<h4>Results</h4>Positive HRNPM status was associated with positive staining for PUMA (P = 0.04), concomitant PUMA and p21 staining (P = 0.005), and VEGF-R2 (P = 0.003). Positive SLC1A5 staining was associated with positive staining of p27 (P = 0.030), PUMA (P = 0.039), concomitant PUMA and p27 staining, and VEGF-R2 (P = 0.039). In non-serous tumors (n = 72), the SLC1A5 positivity was associated with recurrent disease (P = 0.01). In a multivariable logistic regression analysis FIGO-stage (OR = 12.4), tumor grade (OR = 5.1) and SLC1A5 positivity (OR = 0.1) were independent predictive factors for recurrent disease. Disease-free survival (DFS) in women with SLC1A5-positive non-serous tumors was 92% compared with of 66% in patients with SLC1A5-negative non-serous tumors (Log-rank = 15.343; P = 0.008). In Cox analysis with DFS as endpoint, FIGO-stage (HR = 4.5) and SLC1A5 status (HR = 0.3) were prognostic factors.<h4>Conclusions</h4>As the proteins HRNPM and SLC1A5 are associated with the cell cycle regulators p21 or p27, the apoptosis regulators PTEN and PUMA, and the VEGF-R2 it is concluded that both proteins have role in the pathogenesis of ovarian cancer. In patients with non-serous ovarian cancer SLC1A5 protects from recurrent disease, presumably by means of biological mechanisms that are unrelated to cytotoxic drug sensitivity.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0179363&type=printable |
| spellingShingle | Kathrine Bjersand Tomas Seidal Inger Sundström-Poromaa Helena Åkerud Ingiridur Skirnisdottir The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer. PLoS ONE |
| title | The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer. |
| title_full | The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer. |
| title_fullStr | The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer. |
| title_full_unstemmed | The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer. |
| title_short | The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer. |
| title_sort | clinical and prognostic correlation of hrnpm and slc1a5 in pathogenesis and prognosis in epithelial ovarian cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0179363&type=printable |
| work_keys_str_mv | AT kathrinebjersand theclinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT tomasseidal theclinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT ingersundstromporomaa theclinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT helenaakerud theclinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT ingiridurskirnisdottir theclinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT kathrinebjersand clinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT tomasseidal clinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT ingersundstromporomaa clinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT helenaakerud clinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer AT ingiridurskirnisdottir clinicalandprognosticcorrelationofhrnpmandslc1a5inpathogenesisandprognosisinepithelialovariancancer |